These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 30838312)

  • 1. Comparing Risperidone and Olanzapine to Tetrabenazine for the Management of Chorea in Huntington Disease: An Analysis from the Enroll-HD Database.
    Schultz JL; Kamholz JA; Nopoulos PC; Killoran A
    Mov Disord Clin Pract; 2019 Feb; 6(2):132-138. PubMed ID: 30838312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Huntington's disease: role of tetrabenazine.
    de Tommaso M; Serpino C; Sciruicchio V
    Ther Clin Risk Manag; 2011; 7():123-9. PubMed ID: 21479143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tetrabenazine treatment for Huntington's disease-associated chorea.
    Ondo WG; Tintner R; Thomas M; Jankovic J
    Clin Neuropharmacol; 2002; 25(6):300-2. PubMed ID: 12469001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of chorea associated with Huntington's disease: focus on tetrabenazine.
    Setter SM; Neumiller JJ; Dobbins EK; Wood L; Clark J; DuVall CA; Santiago A
    Consult Pharm; 2009 Jul; 24(7):524-37. PubMed ID: 19689181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial.
    Huntington Study Group
    Neurology; 2006 Feb; 66(3):366-72. PubMed ID: 16476934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Pharmacological Approaches to Reduce Chorea in Huntington's Disease.
    Coppen EM; Roos RA
    Drugs; 2017 Jan; 77(1):29-46. PubMed ID: 27988871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of tetrabenazine on gait and functional mobility in individuals with Huntington's disease.
    Kegelmeyer DA; Kloos AD; Fritz NE; Fiumedora MM; White SE; Kostyk SK
    J Neurol Sci; 2014 Dec; 347(1-2):219-23. PubMed ID: 25456459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal Evaluation of the Effect of Tricyclic Antidepressants and Neuroleptics on the Course of Huntington's Disease-Data from a Real World Cohort.
    Achenbach J; Saft C; Faissner S
    Brain Sci; 2021 Mar; 11(4):. PubMed ID: 33805940
    [No Abstract]   [Full Text] [Related]  

  • 9. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators.
    Frank S
    BMC Neurol; 2009 Dec; 9():62. PubMed ID: 20021666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial.
    Furr Stimming E; Claassen DO; Kayson E; Goldstein J; Mehanna R; Zhang H; Liang GS; Haubenberger D;
    Lancet Neurol; 2023 Jun; 22(6):494-504. PubMed ID: 37210099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term effects of tetrabenazine on chorea associated with Huntington's disease.
    Kenney C; Hunter C; Davidson A; Jankovic J
    Mov Disord; 2007 Jan; 22(1):10-3. PubMed ID: 17078062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The long-term effect of tetrabenazine in the management of Huntington disease.
    Fasano A; Cadeddu F; Guidubaldi A; Piano C; Soleti F; Zinzi P; Bentivoglio AR
    Clin Neuropharmacol; 2008; 31(6):313-8. PubMed ID: 19050408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating depression and suicidality in tetrabenazine users with Huntington disease.
    Schultz JL; Killoran A; Nopoulos PC; Chabal CC; Moser DJ; Kamholz JA
    Neurology; 2018 Jul; 91(3):e202-e207. PubMed ID: 29925548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An experimental model for Huntington's chorea?
    Zeef DH; Jahanshahi A; Vlamings R; Casaca-Carreira J; Santegoeds RG; Janssen ML; Oosterloo M; Temel Y
    Behav Brain Res; 2014 Apr; 262():31-4. PubMed ID: 24412685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature.
    Chen JJ; Ondo WG; Dashtipour K; Swope DM
    Clin Ther; 2012 Jul; 34(7):1487-504. PubMed ID: 22749259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease.
    Frank S; Ondo W; Fahn S; Hunter C; Oakes D; Plumb S; Marshall F; Shoulson I; Eberly S; Walker F; Factor S; Hunt V; Shinaman A; Jankovic J
    Clin Neuropharmacol; 2008; 31(3):127-33. PubMed ID: 18520979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease.
    Frank S
    Neuropsychiatr Dis Treat; 2010 Oct; 6():657-65. PubMed ID: 20957126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine.
    Brusa L; Orlacchio A; Moschella V; Iani C; Bernardi G; Mercuri NB
    Mov Disord; 2009 Jan; 24(1):126-9. PubMed ID: 19170197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease.
    Claassen DO; Carroll B; De Boer LM; Wu E; Ayyagari R; Gandhi S; Stamler D
    J Clin Mov Disord; 2017; 4():3. PubMed ID: 28265459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antidopaminergic treatment is associated with reduced chorea and irritability but impaired cognition in Huntington's disease (Enroll-HD).
    Harris KL; Kuan WL; Mason SL; Barker RA
    J Neurol Neurosurg Psychiatry; 2020 Jun; 91(6):622-630. PubMed ID: 32229581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.